GARY A LYONS Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for GARY A LYONS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of GARY A LYONS. GARY A LYONS is in Brickell Biotech, Inc. ($VICL) and Director in VICAL INC ($VICL) and Director in NEUROCRINE BIOSCIENCES INC ($NBIX) and Director in Ardea Biosciences, Inc./DE ($IBPI) and Director in RIGEL PHARMACEUTICALS INC ($RIGL) and Director in CYTORI THERAPEUTICS, INC. ($XMP) and Director in KALOBIOS PHARMACEUTICALS INC ($KBIO) and Director in Novus Therapeutics, Inc. ($TKAI) and Director in Retrophin, Inc. ($RTRX).
Latest Insider Trading Transactions of GARY A LYONS
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, IBPI, VICL, ELDN, KBIO, NBIX, PSTV, RIGL, RTRX
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 18 2021 | RTRX | Travere Therapeuti ... | LYONS GARY A | Director | Option Exercise | A | 18.27 | 9,000 | 164,430 | 9,000 | |
May 18 2021 | RTRX | Travere Therapeuti ... | LYONS GARY A | Director | Grant | A | 0.00 | 3,000 | 0 | 37,000 | 34 K to 37 K (+8.82 %) |
Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 120.00 | 400 | 48,000 | 223,697 | 224.1 K to 223.7 K (-0.18 %) |
Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 120.03 | 1,600 | 192,047 | 224,097 | 225.7 K to 224.1 K (-0.71 %) |
Sep 17 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Option Exercise | A | 0.80 | 60,000 | 48,000 | 60,000 | |
Sep 17 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Grant | A | 0.81 | 11,934 | 9,667 | 24,729 | 12.8 K to 24.7 K (+93.27 %) |
Sep 15 2020 | NVUS | Novus Therapeutics ... | LYONS GARY A | Director | Option Exercise | A | 500.00 | 1,167 | 583,500 | 1,167 | |
Sep 02 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Option Exercise | M | 0.00 | 692 | 0 | 0 | |
Sep 02 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Payment of Exercise | F | 0.94 | 8,631 | 8,113 | 12,795 | 21.4 K to 12.8 K (-40.28 %) |
Sep 02 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Payment of Exercise | F | 0.94 | 346 | 325 | 21,426 | 21.8 K to 21.4 K (-1.59 %) |
Sep 02 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Buy | M | 0.00 | 692 | 0 | 21,772 | 21.1 K to 21.8 K (+3.28 %) |
Aug 04 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Option Exercise | M | 0.00 | 692 | 0 | 692 | |
Aug 04 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Payment of Exercise | F | 0.92 | 346 | 318 | 21,080 | 21.4 K to 21.1 K (-1.61 %) |
Aug 04 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Buy | M | 0.00 | 692 | 0 | 21,426 | 20.7 K to 21.4 K (+3.34 %) |
Jul 02 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Option Exercise | M | 0.00 | 691 | 0 | 1,384 | |
Jul 02 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Payment of Exercise | F | 1.00 | 346 | 346 | 20,734 | 21.1 K to 20.7 K (-1.64 %) |
Jul 02 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Buy | M | 0.00 | 691 | 0 | 21,080 | 20.4 K to 21.1 K (+3.39 %) |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Option Exercise | A | 1.12 | 4,333 | 4,853 | 4,333 | |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Option Exercise | M | 0.00 | 692 | 0 | 692 | |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Option Exercise | M | 0.00 | 692 | 0 | 692 | |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Option Exercise | M | 0.00 | 691 | 0 | 691 | |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Option Exercise | M | 0.00 | 692 | 0 | 692 | |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Option Exercise | M | 0.00 | 3,491 | 0 | 3,491 | |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Grant | A | 0.00 | 17,261 | 0 | 20,389 | 3.1 K to 20.4 K (+551.82 %) |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Payment of Exercise | F | 1.16 | 346 | 401 | 3,128 | 3.5 K to 3.1 K (-9.96 %) |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Buy | M | 0.00 | 692 | 0 | 3,474 | 2.8 K to 3.5 K (+24.87 %) |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Payment of Exercise | F | 1.20 | 346 | 415 | 2,782 | 3.1 K to 2.8 K (-11.06 %) |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Buy | M | 0.00 | 692 | 0 | 3,128 | 2.4 K to 3.1 K (+28.41 %) |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Payment of Exercise | F | 1.19 | 346 | 412 | 2,436 | 2.8 K to 2.4 K (-12.44 %) |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Buy | M | 0.00 | 691 | 0 | 2,782 | 2.1 K to 2.8 K (+33.05 %) |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Payment of Exercise | F | 2.93 | 346 | 1,014 | 2,091 | 2.4 K to 2.1 K (-14.20 %) |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Buy | M | 0.00 | 692 | 0 | 2,437 | 1.7 K to 2.4 K (+39.66 %) |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Payment of Exercise | F | 1.16 | 1,746 | 2,025 | 1,745 | 3.5 K to 1.7 K (-50.01 %) |
Jun 05 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Director | Buy | M | 0.00 | 3,491 | 0 | 3,491 | 0 to 3.5 K |
May 21 2020 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 119.93 | 6,018 | 721,739 | 6,018 | |
May 19 2020 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
May 19 2020 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Grant | A | 0.00 | 3,000 | 0 | 34,000 | 31 K to 34 K (+9.68 %) |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
Feb 19 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Option Exercise | A | 1.16 | 8,333 | 9,666 | 8,333 | ||
Feb 19 2020 | VICL | Brickell Biotech, ... | LYONS GARY A | Option Exercise | A | 1.16 | 2,167 | 2,514 | 2,167 | ||
Nov 13 2019 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 110.00 | 5,000 | 550,000 | 225,697 | 230.7 K to 225.7 K (-2.17 %) |
Nov 05 2019 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 100.22 | 5,000 | 501,104 | 230,697 | 235.7 K to 230.7 K (-2.12 %) |
Jul 31 2019 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 92.07 | 10,000 | 920,686 | 235,697 | 245.7 K to 235.7 K (-4.07 %) |
Jul 15 2019 | NVUS | Novus Therapeutics ... | LYONS GARY A | Director | Option Exercise | A | 0.88 | 20,000 | 17,600 | 20,000 | |
May 24 2019 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 2.02 | 55,000 | 111,100 | 55,000 | |
May 23 2019 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 79.79 | 10,000 | 797,900 | 10,000 | |
May 10 2019 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Option Exercise | A | 17.94 | 8,000 | 143,520 | 8,000 | |
May 10 2019 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Grant | A | 0.00 | 2,000 | 0 | 31,000 | 29 K to 31 K (+6.90 %) |
Nov 05 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 114.41 | 15,000 | 1,716,213 | 245,697 | 260.7 K to 245.7 K (-5.75 %) |
Jun 15 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 99.24 | 15,000 | 1,488,549 | 260,697 | 275.7 K to 260.7 K (-5.44 %) |
Jun 14 2018 | NVUS | Novus Therapeutics ... | LYONS GARY A | Director | Option Exercise | A | 6.18 | 9,100 | 56,238 | 9,100 | |
May 25 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 94.64 | 12,500 | 1,183,000 | 12,500 | |
May 25 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 94.64 | 12,500 | 1,183,000 | 12,500 | |
May 24 2018 | VICL | VICAL INC | LYONS GARY A | Director | Option Exercise | A | 1.67 | 6,500 | 10,855 | 6,500 | |
May 18 2018 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 3.98 | 40,000 | 159,200 | 40,000 | |
May 11 2018 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Option Exercise | A | 26.52 | 10,000 | 265,200 | 10,000 | |
May 11 2018 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Grant | A | 0.00 | 2,500 | 0 | 29,000 | 26.5 K to 29 K (+9.43 %) |
Apr 05 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | M | 7.05 | 15,000 | 105,750 | 0 | |
Apr 05 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Payment of Exercise | F | 77.23 | 1,369 | 105,728 | 275,697 | 277.1 K to 275.7 K (-0.49 %) |
Apr 05 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Buy | M | 7.05 | 15,000 | 105,750 | 277,066 | 262.1 K to 277.1 K (+5.72 %) |
Feb 20 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 84.67 | 5,000 | 423,341 | 262,066 | 267.1 K to 262.1 K (-1.87 %) |
Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 83.08 | 5,000 | 415,380 | 267,066 | 272.1 K to 267.1 K (-1.84 %) |
Dec 05 2017 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 72.92 | 10,000 | 729,182 | 272,066 | 282.1 K to 272.1 K (-3.55 %) |
Jul 05 2017 | TKAI | Novus Therapeutics ... | LYONS GARY A | Director | Option Exercise | A | 5.85 | 18,000 | 105,300 | 18,000 | |
Jun 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 53.64 | 15,000 | 804,600 | 15,000 | |
May 30 2017 | VICL | VICAL INC | LYONS GARY A | Director | Option Exercise | A | 2.36 | 6,500 | 15,340 | 6,500 | |
May 18 2017 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Option Exercise | A | 17.44 | 10,000 | 174,400 | 10,000 | |
May 18 2017 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Grant | A | 0.00 | 2,500 | 0 | 26,500 | 24 K to 26.5 K (+10.42 %) |
May 12 2017 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 2.61 | 40,000 | 104,400 | 40,000 | |
Feb 15 2017 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | M | 3.40 | 15,000 | 51,000 | 0 | |
Feb 15 2017 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Buy | M | 3.40 | 15,000 | 51,000 | 282,066 | 267.1 K to 282.1 K (+5.62 %) |
Jan 27 2017 | XMP | CYTORI THERAPEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 1.56 | 25,000 | 39,000 | 25,000 | |
Dec 07 2016 | VICL | VICAL INC | LYONS GARY A | Director | Sell | S | 2.30 | 7,078 | 16,248 | 7,828 | 14.9 K to 7.8 K (-47.48 %) |
Jun 16 2016 | XMP | CYTORI THERAPEUTIC ... | LYONS GARY A | Director | Option Exercise | X | 3.06 | 950 | 2,907 | 950 | |
Jun 16 2016 | XMP | CYTORI THERAPEUTIC ... | LYONS GARY A | Director | Option Exercise | X | 2.55 | 1,900 | 4,845 | 0 | |
Jun 16 2016 | XMP | CYTORI THERAPEUTIC ... | LYONS GARY A | Director | Buy | X | 0.00 | 1,900 | 0 | 4,358 | 2.5 K to 4.4 K (+77.30 %) |
Jun 06 2016 | VICL | VICAL INC | LYONS GARY A | Director | Buy | P | 4.39 | 7,078 | 31,089 | 14,906 | 7.8 K to 14.9 K (+90.42 %) |
May 24 2016 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 47.89 | 15,000 | 718,350 | 15,000 | |
May 24 2016 | VICL | VICAL INC | LYONS GARY A | Director | Option Exercise | A | 0.36 | 65,000 | 23,465 | 65,000 | |
May 19 2016 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Option Exercise | A | 16.33 | 8,000 | 130,640 | 8,000 | |
May 19 2016 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Grant | A | 0.00 | 2,000 | 0 | 24,000 | 22 K to 24 K (+9.09 %) |
May 12 2016 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 2.40 | 40,000 | 96,000 | 40,000 | |
May 10 2016 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | M | 3.07 | 15,000 | 46,050 | 0 | |
May 10 2016 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Buy | M | 3.07 | 15,000 | 46,050 | 267,066 | 252.1 K to 267.1 K (+5.95 %) |
Jan 04 2016 | XMP | CYTORI THERAPEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 0.00 | 53,820 | 0 | 99,820 | |
Sep 21 2015 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 54.66 | 5,000 | 273,300 | 252,066 | 257.1 K to 252.1 K (-1.95 %) |
Sep 21 2015 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 55.00 | 10,000 | 550,000 | 257,066 | 267.1 K to 257.1 K (-3.74 %) |
Jul 14 2015 | KBIO | KALOBIOS PHARMACEU ... | LYONS GARY A | Director | Option Exercise | A | 3.68 | 5,000 | 18,400 | 5,000 | |
Jun 10 2015 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Option Exercise | A | 32.59 | 8,000 | 260,720 | 8,000 | |
Jun 10 2015 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Grant | A | 0.00 | 2,000 | 0 | 22,000 | 20 K to 22 K (+10.00 %) |
Jun 01 2015 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 42.76 | 25,000 | 1,069,000 | 25,000 | |
May 26 2015 | VICL | VICAL INC | LYONS GARY A | Director | Option Exercise | A | 0.89 | 50,000 | 44,500 | 50,000 | |
May 26 2015 | VICL | VICAL INC | LYONS GARY A | Director | Grant | A | 0.01 | 7,500 | 75 | 78,281 | 70.8 K to 78.3 K (+10.60 %) |
May 18 2015 | XMP | CYTORI THERAPEUTIC ... | LYONS GARY A | Director | Grant | A | 0.00 | 12,440 | 0 | 12,440 | 0 to 12.4 K |
May 14 2015 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 3.96 | 40,000 | 158,400 | 40,000 | |
Mar 24 2015 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 41.53 | 30,000 | 1,245,900 | 267,066 | 297.1 K to 267.1 K (-10.10 %) |
Apr 15 2005 | IBPI | Ardea Biosciences, ... | LYONS GARY A | Director | Option Exercise | A | 4.08 | 17,500 | 71,400 | 62,499 | |
Jun 15 2004 | IBPI | Ardea Biosciences, ... | LYONS GARY A | Director | Option Exercise | A | 13.93 | 2,500 | 34,825 | 44,999 | |
Jun 15 2004 | IBPI | Ardea Biosciences, ... | LYONS GARY A | Director | Option Exercise | A | 13.93 | 15,000 | 208,950 | 42,499 | |
Feb 04 2004 | IBPI | Ardea Biosciences, ... | LYONS GARY A | Director | Option Exercise | A | 16.49 | 10,000 | 164,900 | 27,499 | |
Feb 04 2004 | IBPI | Ardea Biosciences, ... | LYONS GARY A | Director | Option Exercise | A | 16.49 | 10,000 | 164,900 | 17,499 |
Page: 1